Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours

Trial Profile

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2019

At a glance

  • Drugs Volasertib (Primary) ; Itraconazole
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Jun 2019 Planned End Date changed from 15 Apr 2019 to 15 Sep 2019.
    • 31 Oct 2018 Planned End Date changed from 15 Oct 2018 to 15 Apr 2019.
    • 01 Jun 2018 Planned End Date changed from 15 Jun 2018 to 15 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top